MedTrace Logo

A Single-Arm Exploratory Study of NatureU Histra Disslove on Chronic Urticaria Symptoms

NCT07611032 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-05-28

No results posted yet for this study

Summary

This was a single-center, open-label, single-arm, exploratory self-controlled study evaluating NatureU Histra Disslove in adults with chronic urticaria symptoms. Twenty-four participants were screened, 19 participants were enrolled, and 19 participants completed the study and were included in the effectiveness analysis. Participants took one tablet of the study product orally once daily, 20 minutes before a main meal, for 28 consecutive days. Urticaria Control Test, Urticaria Activity Score 7, and Dermatology Life Quality Index assessments were performed at baseline, Day 14, and Day 28. Safety was monitored during the study.

Conditions

  • Chronic Urticaria
  • Urticaria
  • Angioedema

Interventions

DIETARY_SUPPLEMENT

NatureU Histra Disslove

NatureU Histra Disslove is a food product containing active diamine oxidase (DAO). Participants took one tablet orally once daily, 20 minutes before a main meal, preferably dinner, for 28 consecutive days.

Sponsors & Collaborators

  • OmniSolutions Laboratory Holdings Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-04
Primary Completion
2024-11-01
Completion
2024-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07611032 on ClinicalTrials.gov